-
August 1, 2022
R&D Pipeline as of August 2022 -
August 1, 2022
The First Quarter of FY2022 (August 1, 2022) -
May 10, 2022
Financial Results(May 10, 2022) -
February 1, 2022
The Third Quarter of FY2021(April 2021- December 2021) -
November 9, 2021
The Second Quarter of FY2021 (April 2021 - September 2021)
-
July 27, 2022
Notice on the release by ObsEva, the licensee of "Linzagolix", GnRH antagonist -
July 6, 2022
Kissei Initiates Phase III Clinical Trial for GnRH antagonist Linzagolix in Japanese Patients with uterine fibroids -
June 17, 2022
Marketing authorization in Europe for GnRH antagonist Linzagolix -
June 6, 2022
Launch of TAVNEOS® Capsules 10mg, a selective Complement C5a Receptor Antagonist -
May 30, 2022
"CAROGRA® Tablets", Launched in Japan for Treatment of Ulcerative Colitis
－ The World-First Orally Available α4 Integrin Antagonist Come onto the Market －
